77 completed, 6 unknown, 2 not yet recruiting, 2 withdrawn. 90 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 90 | Completed 77, Unknown 6, Not yet recruiting 2, Withdrawn 2, Active not recruiting 1, Recruiting 1, Terminated 1 |
| Phase 2 | 4 | Unknown 2, Completed 1, Not yet recruiting 1 |
Follow Rhinitis, Allergic, Perennial: new trials by email Literature Review of Rhinitis, Allergic, Perennial trials Research Report on Rhinitis, Allergic, Perennial
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Potency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in HDM Allergic Patients With Severe Asthma, Treated With Tezepelumab Tezepelumab, Acarizax, Placebo - Severe Asthma, Allergy to House Dust Mites | Phase 3 | Not yet recruiting | University Hospital, Montpellier | 38 | 2025-07-15 | 2025-06-10 |
| Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or Df Allergen Immunotherapy Extract - Rhinitis, Rhinoconjunctivitis | Phase 3 | Recruiting | Inmunotek S.L. | 736 | 2025-04-02 | 2026-01-16 |
| A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM) PURETHAL Mites 50,000 AUeq/ml, Biological/Vaccine: Placebo - House Dust Mite Allergy, House Dust Mite Rhinitis | Phase 3 | Completed | HAL Allergy | 691 | 2024-09-09 | 2026-08-10 |
| Efficacy/ Safety of Product CM9241GRU in Patients With Perennial Allergic Rhinitis Product CM9241GRU, Placebo - Rhinitis, Allergic, Perennial | Phase 3 | Unknown | Ache Laboratorios Farmaceuticos S.A. | 432 | 2024-09-01 | 2024-08-29 |
| A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1) LY3650150, Placebo, Standard therapy for INCS - Perennial Allergic Rhinitis (PAR) | Phase 3 | Active not recruiting | Eli Lilly and Company | 450 | 2024-04-26 | 2026-10-27 |
| Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract 3,000 MM09, 9,000 MM09, Placebo sublingual - Allergic Rhinitis, Allergic Asthma | Phase 2 / Phase 3 | Not yet recruiting | Inmunotek S.L. | 90 | 2023-11-01 | 2023-10-23 |
| Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivitis MM09 allergoid-mannan conjugates subcutaneous (3.000 UTm/mL), MM09 allergoid-mannan conjugates Sublingual (3.000 UTm/mL), MM09 allergoid-mannan conjugates Sublingual (9.000 UTm/mL) - House Dust Mite Allergy, Perennial Allergic Rhinitis | Phase 3 | Unknown | Inmunotek S.L. | 400 | 2022-12-01 | 2022-11-18 |
| Observation on the Efficacy and Mechanism of SLIT With Dust Mite Allergen for PAR Dust mite drops (trade name: Changdi, Zhejiang Tawu Biotechnology Co. Ltd.). - Allergic Rhinitis | Phase 2 / Phase 3 | Unknown | People's Hospital of Anshun City of Guizhou Province | 60 | 2022-12-01 | 2022-10-06 |
| As Needed Versus Regular Intranasal Corticosteroid in Children With Perennial Allergic Rhinitis Intranasal Drug (INCS = Fluticasone furoate nasal spray, Placebo = Normal saline nasal spray) - Perennial Allergic Rhinitis, Child, Only | Phase 3 | Completed | Mahidol University | 68 | 2022-04-04 | 2025-11-18 |
| Efficacy and Safety Assessment of Beltavac® With Polymerized Extract of HDM House dust mites allergoid from Dermatophagoides pteronyssinus and Dermatophagoides farinae, Placebo - House Dust Mite Allergy | Phase 3 | Unknown | Probelte Pharma S.L.U. | 350 | 2022-01-17 | 2024-07-18 |
| Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis MM09-MG01(30.000-30.000), MG01(30.000), MM09(30.000) - Allergic Rhinoconjunctivitis, Perennial Allergic Rhinitis | Phase 3 | Terminated | Inmunotek S.L. | 18 | 2021-04-30 | 2023-12-19 |
| Clinical Study, Non Inferiority Between Noex® 50µg Versus Busonid® 50µg in Treatment of Allergic Rhinitis Budesonid 50mcg (Noex), Budesonid 50mcg (Busonid) - Rhinitis, Allergic, Perennial | Phase 3 | Withdrawn | Eurofarma Laboratorios S.A. | 2019-10-08 | 2019-10-09 | |
| Efficacy and Safety of HCP1102 Capsule in Patients With Perennial Allergic Rhinitis HCP1102, HGP1408 - Perennial Allergic Rhinitis | Phase 3 | Completed | Hanmi Pharmaceutical Company Limited | 174 | 2018-10-23 | 2020-03-27 |
| To Evaluate the Efficacy and Safety of HL151 Versus Placebo in Perennial Allergic Rhinitis Patients HL151, placebo - Perennial Allergic Rhinitis | Phase 3 | Completed | Hanlim Pharm. Co., Ltd. | 272 | 2017-02-07 | 2018-08-31 |
| Efficacy and Safety of So-Cheong-Ryong-Tang on Perennial Allergic Rhinitis SCRT, Placebos - Perennial Allergic Rhinitis | Phase 3 | Unknown | Kyung Hee University Hospital at Gangdong | 154 | 2016-12-31 | 2017-03-14 |
| A Study to Assess Efficacy and Safety of Nasacort® Nasal Spray in Comparison With Flixonase® Nasal Spray in Adults Suffering From Perennial Allergic Rhinitis (PAR) triamcinolone XRG5029, fluticasone - Rhinitis Allergic | Phase 3 | Completed | Sanofi | 260 | 2016-11-30 | 2022-04-25 |
| Clinical Study, Non Inferiority Between Noex® 32µg Versus Budecort Aqua® 32µg in Treatment of Alergic Rhinitis Budesonide - Rhinitis, Allergic, Perennial | Phase 3 | Withdrawn | Eurofarma Laboratorios S.A. | 2016-06-01 | 2019-10-09 | |
| Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR) GSP 301 NS, GSP 301 Placebo NS pH 3.7, GSP 301 Placebo NS pH 7.0 - Perennial Allergic Rhinitis | Phase 3 | Completed | Glenmark Specialty S.A. | 601 | 2016-04-01 | 2020-02-26 |
| Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR 300 IR, Placebo - Rhinitis, Allergic, Perennial, House Dust Mite Allergy | Phase 3 | Completed | Stallergenes Greer | 1607 | 2015-09-29 | 2019-10-14 |
| Clinical Trial to Evaluate the Efficacy and Safety of CKD-342 CKD-342, Mometasone furoate, Levocabastine HCL - Rhinitis, Allergic, Perennial | Phase 3 | Completed | Chong Kun Dang Pharmaceutical | 459 | 2015-05-01 | 2016-12-26 |
Showing 20 of 90. Sign in to see all of them.
Rhinitis, Allergic (22) · Rhinitis, Allergic, Seasonal (13) · Dust Mite Allergy (11) · Hypersensitivity (8) · Rhinitis (8) · Asthma (3) · Conjunctivitis (1) · Immune System Diseases (1) · Nasal Obstruction (1) · Nose Diseases (1) · Respiratory Hypersensitivity (1) · Respiratory Tract Diseases (1) · Rhinorrhea (1) · Sneezing (1)
Hypersensitivity, Immediate (90) · Otorhinolaryngologic Diseases (90) · Immune System Diseases (89) · Nose Diseases (89) · Respiratory Hypersensitivity (89) · Respiratory Tract Diseases (89) · Hypersensitivity (82) · Rhinitis (82) · Rhinitis, Allergic (68) · Infections (8) · Respiratory Tract Infections (8) · Bronchial Diseases (3) · Lung Diseases (3) · Lung Diseases, Obstructive (3)
Mometasone Furoate (11) · ciclesonide (8) · Fluticasone (4) · montelukast (4) · Beclomethasone (3) · Cetirizine (3) · azelastine (3) · Nasal Sprays (2) · Pseudoephedrine (2) · Triamcinolone (2) · bepotastine besilate (2) · desloratadine (2) · fluticasone furoate (2) · Antigens, Dermatophagoides (1) · Biological Products (1)
GlaxoSmithKline (16) · Organon and Co (11) · AstraZeneca (7) · Sumitomo Pharma America, Inc. (7) · Inmunotek S.L. (4) · ALK-Abelló A/S (3) · Meda Pharmaceuticals (3) · Sanofi (3) · Tanabe Pharma Corporation (3) · Teva Branded Pharmaceutical Products R&D, Inc. (3) · Boehringer Ingelheim (2) · Eurofarma Laboratorios S.A. (2) · Hanlim Pharm. Co., Ltd. (2) · Hanmi Pharmaceutical Company Limited (2) · Ache Laboratorios Farmaceuticos S.A. (1)
United States (33) · South Korea (9) · Japan (6) · Canada (4) · China (4) · Germany (4) · Spain (4) · Argentina (3) · Brazil (3) · Belgium (2) · France (2) · Latvia (2) · Lithuania (2) · Poland (2) · Taiwan (2)
Ana Isabel Tabar Purroy, MD. PhD (1) · Ana Isabel Tabar Purroy, MD; PhD (1) · Annemie Narkus, M.D. (1) · Bok Yang Pyun, MD (1) · Chae-Seo Rhee, M.D. (1) · Chang-Hoon Kim, M.D. (1) · Dae Hyun Lim, MD (1) · Dae-Woo Kim, M.D. (1)
PMID 22737708, PMID 26364765, PMID 29656145, PMID 12668793, PMID 14674933, PMID 15313870, PMID 15461603, PMID 15516669, PMID 15750716, PMID 15898976, PMID 16930249, PMID 17619558, PMID 17651373, PMID 18164990, PMID 18331513, PMID 18517083, PMID 18517084, PMID 19441606, PMID 19624554, PMID 19925886, PMID 19968632, PMID 20545698, PMID 20624650, PMID 20816182, PMID 21122901, PMID 21783242, PMID 21888757, PMID 22077106, PMID 22092947, PMID 22224763, PMID 22370530, PMID 22627366, PMID 23026182, PMID 23062389, PMID 23348417, PMID 23791985, PMID 24169062, PMID 24169063, PMID 24468255, PMID 24631153, PMID 24679069, PMID 24992552, PMID 25171868, PMID 25644617, PMID 25685162, PMID 26141263, PMID 26507709, PMID 26874355, PMID 26922931, PMID 26932169
2023 (2), 2004 (1), 2018 (1), 2025 (1)